Herrmann E - Search Results

1

Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib.

Peveling-Oberhag J, Döring C, Hartmann S, Filmann N, Mertens A, Piiper A, Herrmann E, Hansmann ML, Zeuzem S, Trojan J, Welker MW. Peveling-Oberhag J, et al. Among authors: herrmann e. Clin Sci (Lond). 2015 Jan;128(1):29-37. doi: 10.1042/CS20140007. Clin Sci (Lond). 2015. PMID: 24959956

2

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a.

Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, Roth WK. Zeuzem S, et al. Among authors: herrmann e. Gastroenterology. 2001 May;120(6):1438-47. doi: 10.1053/gast.2001.24006. Gastroenterology. 2001. PMID: 11313314 Clinical Trial.

3

Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy.

Sarrazin C, Bruckner M, Herrmann E, Rüster B, Bruch K, Roth WK, Zeuzem S. Sarrazin C, et al. Among authors: herrmann e. Virology. 2001 Oct 10;289(1):150-63. doi: 10.1006/viro.2001.1092. Virology. 2001. PMID: 11601926 Free article.

4

First-phase parameters in hepatitis C viral kinetics.

Zeuzem S, Herrmann E. Zeuzem S, et al. Among authors: herrmann e. J Viral Hepat. 2002 Sep;9(5):332-3. doi: 10.1046/j.1365-2893.2002.00375.x. J Viral Hepat. 2002. PMID: 12225326 No abstract available.

5

Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses.

Sarrazin C, Herrmann E, Bruch K, Zeuzem S. Sarrazin C, et al. Among authors: herrmann e. J Virol. 2002 Nov;76(21):11079-90. doi: 10.1128/jvi.76.21.11079-11090.2002. J Virol. 2002. PMID: 12368350 Free PMC article.

6

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy.

Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S. Berg T, et al. Among authors: herrmann e. Hepatology. 2003 Mar;37(3):600-9. doi: 10.1053/jhep.2003.50106. Hepatology. 2003. PMID: 12601358

7

Hepatitis C viral kinetic models.

Herrmann E, Zeuzem S. Herrmann E, et al. Cell Death Differ. 2003 Jan;10 Suppl 1:S7-8. doi: 10.1038/sj.cdd.4401118. Cell Death Differ. 2003. PMID: 12655337 Review. No abstract available.

8

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.

Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Herrmann E, et al. Hepatology. 2003 Jun;37(6):1351-8. doi: 10.1053/jhep.2003.50218. Hepatology. 2003. PMID: 12774014 Clinical Trial.

9

Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.

Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, Herrmann E, Spengler U, Goeser T, Nasser S, Wursthorn K, Pape GR, Hopf U, Zeuzem S. Berg T, et al. Among authors: herrmann e. Hepatology. 2003 Jun;37(6):1359-67. doi: 10.1053/jhep.2003.50219. Hepatology. 2003. PMID: 12774015 Clinical Trial.

10

Pharmacokinetics of peginterferons.

Zeuzem S, Welsch C, Herrmann E. Zeuzem S, et al. Among authors: herrmann e. Semin Liver Dis. 2003;23 Suppl 1:23-8. doi: 10.1055/s-2003-41631. Semin Liver Dis. 2003. PMID: 12934165 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

863 results

Search Page